Cumberland Pharmaceuticals Inc. Q4 FY2025 earnings call

• Financial performance: 2025 was a strong year with revenue growth leading to adjusted earnings turnaround and improved cash flow from operations. Balance sheet was strengthened by increasing shareholder equity and reducing line of credit balance. - Global expansion: Vibative expanded globally with approval in China and launch in Saudi Arabia; ibuprofen injection approved in Mexico. - Business development: Added Talicia, an FDA-approved treatment for Helicobacter pylori infections; CMS issued J-code for Caldolor enhancing reimbursement. - Clinical programs: Advanced clinical pipeline with breakthrough results from Fight DMD study; Fitraban product candidate showed positive results in Duchenne muscular dystrophy study; ifitroban got orphan drug, rare pediatric disease, and fast track designations; ongoing clinical studies in systemic sclerosis and idiopathic pulmonary fibrosis. - Brand updates: Vibative had market expansions and partnerships; Crystalose took actions to address substitution; Caldolor got new pediatric labeling and study published; Sancuso had favorable sales and new website launch; Talicia launched with co-commercialization agreement

Fourth quarter 2025: Portfolio of FDA-approved brands had combined revenues of $13.7 million, a 31% increase over the prior year period. For the full year, revenues totaled $44.5 million, an 18% increase over 2024. Adjusted earnings improved by over $2 million to $1.7 million, or 11 cents a share. Cash flow from operations improved by $5.5 million to just under $5 million for the full year. Revenue contribution by product in the fourth quarter: Crystalos at $3.1 million, Sancuso at $3.3 million, Vibative at $2.8 million, Caldolor at $0.9 million, and Talicia at $3.3 million. Full year 2025 product revenues: Crystalos at $10.5 million, Sancuso at $11.9 million, Vibative at $9.4 million, Caldolor at $4.7 million, and Talicia at $3.3 million. Additionally, Vibative received regulatory approval in China and was launched in Saudi Arabia, and ibuprofen injection received regulatory approval in Mexico

• Target to achieve double-digit revenue growth in 2026 driven by in-line brands, sales from Talicia, and growing international business. - Aim for meaningful positive cash flow from operations

• Factors affecting future results include natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics, etc., as detailed in the company's annual report on Form 10-K and subsequent SEC filings